Citius Oncology Inc
CTOR1.390USD
+0.250+21.93%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
99.46MMarket Cap
LossP/E TTM
More Details of Citius Oncology Inc Company
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
Citius Oncology Inc Info
Ticker SymbolCTOR
Company nameCitius Oncology Inc
IPO dateOct 14, 2022
CEOMazur (Leonard)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endOct 14
Address11 Commerce Drive
CityCRANFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07016
Phone19089676677
Websitehttps://citiusonc.com/
Ticker SymbolCTOR
IPO dateOct 14, 2022
CEOMazur (Leonard)
Company Executives of Citius Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jaime Bartushak
Mr. Jaime Bartushak
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
1.65M
--
Mr. Joel Mayersohn
Mr. Joel Mayersohn
Director
Director
621.23K
+2826.46%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Independent Director
Independent Director
600.00K
--
Mr. Myron Holubiak
Mr. Myron Holubiak
Executive Vice Chairman of the Board, Secretary, Director
Executive Vice Chairman of the Board, Secretary, Director
--
--
Ms. Carol Webb
Ms. Carol Webb
Independent Director
Independent Director
--
--
Dr. Eugene Holuka
Dr. Eugene Holuka
Independent Director
Independent Director
--
--
Mr. Leonard Mazur
Mr. Leonard Mazur
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Suren Dutia
Mr. Suren Dutia
Independent Director
Independent Director
--
--
Mr. Robert Smith
Mr. Robert Smith
Independent Director
Independent Director
--
--
Dr. Myron S. Czuczman, M.D.
Dr. Myron S. Czuczman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jaime Bartushak
Mr. Jaime Bartushak
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
1.65M
--
Mr. Joel Mayersohn
Mr. Joel Mayersohn
Director
Director
621.23K
+2826.46%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Independent Director
Independent Director
600.00K
--
Mr. Myron Holubiak
Mr. Myron Holubiak
Executive Vice Chairman of the Board, Secretary, Director
Executive Vice Chairman of the Board, Secretary, Director
--
--
Ms. Carol Webb
Ms. Carol Webb
Independent Director
Independent Director
--
--
Dr. Eugene Holuka
Dr. Eugene Holuka
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Citius Pharmaceuticals Inc
77.89%
Armistice Capital LLC
9.05%
Mazur (Leonard L)
4.01%
10XYZ Holdings LP
2.33%
Holubiak (Myron Z)
2.00%
Other
4.71%
Shareholders
Shareholders
Proportion
Citius Pharmaceuticals Inc
77.89%
Armistice Capital LLC
9.05%
Mazur (Leonard L)
4.01%
10XYZ Holdings LP
2.33%
Holubiak (Myron Z)
2.00%
Other
4.71%
Shareholder Types
Shareholders
Proportion
Corporation
80.22%
Individual Investor
14.18%
Hedge Fund
9.15%
Research Firm
0.41%
Investment Advisor/Hedge Fund
0.29%
Investment Advisor
0.24%
Venture Capital
0.15%
Family Office
0.04%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
46
8.69M
7.64%
--
2025Q3
48
8.69M
8.51%
+8.12M
2025Q2
45
642.07K
10.03%
+122.48K
2025Q1
46
519.59K
10.53%
-7.01M
2024Q4
47
615.46K
10.52%
+143.23K
2024Q3
43
472.23K
10.87%
-3.52M
2024Q2
41
3.99M
111.28%
-380.05K
2024Q1
40
4.37M
77.19%
-2.53M
2023Q4
34
6.07M
68.43%
+555.45K
2023Q3
31
5.51M
62.87%
+423.72K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Citius Pharmaceuticals Inc
66.05M
79.09%
--
--
Sep 10, 2025
Mazur (Leonard L)
1.70M
2.04%
+1.70M
--
Sep 19, 2025
10XYZ Holdings LP
1.98M
2.37%
-65.05K
-3.18%
Aug 13, 2024
Holubiak (Myron Z)
850.00K
1.02%
+850.00K
--
Sep 19, 2025
Bartushak (Jaime)
825.00K
0.99%
+825.00K
--
Sep 19, 2025
Czuczman (Myron)
825.00K
0.99%
+825.00K
--
Sep 19, 2025
Mayersohn (Joel)
321.23K
0.38%
+300.00K
+1413.23%
Sep 19, 2025
Holuka (Eugene Myron)
300.00K
0.36%
+300.00K
--
Sep 19, 2025
Webb (Carol A)
300.00K
0.36%
+300.00K
--
Sep 19, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Citius Oncology Inc?
The top five shareholders of Citius Oncology Inc are:
Citius Pharmaceuticals Inc holds 66.05M shares, accounting for 79.09% of the total shares.
Mazur (Leonard L) holds 1.70M shares, accounting for 2.04% of the total shares.
10XYZ Holdings LP holds 1.98M shares, accounting for 2.37% of the total shares.
Holubiak (Myron Z) holds 850.00K shares, accounting for 1.02% of the total shares.
Bartushak (Jaime) holds 825.00K shares, accounting for 0.99% of the total shares.
Citius Pharmaceuticals Inc holds 66.05M shares, accounting for 79.09% of the total shares.
Mazur (Leonard L) holds 1.70M shares, accounting for 2.04% of the total shares.
10XYZ Holdings LP holds 1.98M shares, accounting for 2.37% of the total shares.
Holubiak (Myron Z) holds 850.00K shares, accounting for 1.02% of the total shares.
Bartushak (Jaime) holds 825.00K shares, accounting for 0.99% of the total shares.
What are the top three shareholder types of Citius Oncology Inc?
The top three shareholder types of Citius Oncology Inc are:
Citius Pharmaceuticals Inc
Armistice Capital LLC
Mazur (Leonard L)
Citius Pharmaceuticals Inc
Armistice Capital LLC
Mazur (Leonard L)
How many institutions hold shares of Citius Oncology Inc (CTOR)?
As of 2025Q4, 46 institutions hold shares of Citius Oncology Inc, with a combined market value of approximately 8.69M, accounting for 7.64% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.87%.
What is the biggest source of revenue for Citius Oncology Inc?
In --, the -- business generated the highest revenue for Citius Oncology Inc, amounting to -- and accounting for --% of total revenue.
